Skip to main content
Articles & Publications , Thierry Van Nieuwenhove

Translational Pharmaceutics® Platform Remains a Primary Goal for Quotient Sciences

In this article by 247 BioPharma, Thierry Van Nieuwenhove, the CEO of Quotient Sciences discusses the primary company goals and what steps the Quotient Sciences is taking to meet evolving regulatory requirements.

In addition, Thierry talks about the importance of partnerships and collaborations for the Quotient Sciences growth strategy and what key innovations, or new products will company be showcasing at CPHI Milan this year.

Continue reading the full article or watching the video on 247Bio Pharma.

Latest news from Quotient Sciences

More News
Articles & Publications, News & Announcements, Matt Paterson First-in-human is not just about safety By: Matt Paterson
Read More
News & Announcements, Articles & Publications, Philadelphia, PA, Marlene Leuenberger Marlene Leuenberger featured in CPHI Online's "A Day in the Life of a Vice President and General Manager" By: Marlene Leuenberger
Read More
Let's Talk
Your breakthrough therapy deserves momentum, and every day matters. Start a conversation with us today.